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Abstract This study was conducted with the purpose of
researching the effect of lycopene application on lipopro-
tein, paraoxonase (PON) and cytokines that are projected to
be used in the diagnosis and treatment of diabetes by
making experimental diabetes. At the end of a 1-month
trial period, under ether anesthesia with jelly tubes, blood
samples were taken from rat hearts. Blood samples were
centrifuged and serum was obtained. From the serum
samples, HbA1c, paraoxonase activity, lipoprotein levels
and cytokines were determined. HbA1c levels and PON
activity were found to be p \ 0.001. At the triglyceride
level, with regard to the control group, in all the groups a
significant rise occurred (p B 0.001). At the cholesterol
level, with regard to the control group, a decline was
observed in the other groups (p \ 0.05). At the VLDL
level, with regard to the control group, a significant rise
was observed in the other groups (p \ 0.05). At the HDL
(p \ 0.001) and LDL (p \ 0.05) levels, with regard to the
control group, a significant decline was observed in the
other groups. At the TNF-a, IL-2, IL-6 and IL-10 levels no
difference was found (p [ 0.05). Experimental diabetes
models have an important place in analyzing diabetes
complications and determining treatment approaches.
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Introduction
Diabetes is an ever-growing chronic metabolism defect all
over the world (Seghrouchni et al. 2002). Lifelong and
requiring constant follow up and treatment, diabetes mel-
litus (DM) decreases the patient’s quality of life consid-
erably because of its acute and chronic complications; it is
a chronic, metabolic disease, the morbidity, mortality and
economic burden on society of which are high. Deficiency
of insulin in target tissue or anomaly of its effect causes
disorder in carbon hydrate as well as lipid and protein
metabolism (Onat et al. 2006). The other factors involved
with the occurrence of the disease are heredity, adiposity,
pregnancy, giving birth often, long-duration drug use
(diuretic, corticosteroid, etc.), infections, psychological or
physical trauma and some pancreatic diseases (Sheweita
et al. 2002).
Carotenoids protect human lymphocytes from O2 dam-
age and decrease the risks of some diseases and some
degenerative disorders including some cancer types.
Lycopene has a higher capacity antioxidant effect because
of the fact that the b cycle in its structure is opened (Mayne
1996; Miller et al. 1996).
Arylesterases, namely, paraoxonase (PON-1), are cal-
cium ligating ester hydrolases in A group aryldialkylpho-
sphatase-type, high-density lipoproteins (HDLs) according
to the system of Aldridge (Antikainen et al. 1996). PON-1
has been studied in the field of toxicology because of its
feature of hydrolyzing organophosphate compounds; in
recent years it has gained currency by considering that
people may be protected from KAH risks because of its
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antioxidant effect. Serum PON enzyme is an enzyme
related to HDL, and it is thought to have an antioxidant
function (Erden 2004). Experimental studies have shown
that HDL-K of PON-1 is related to Apo-A1 and APO-J
(Clustrein) proteins (Abbot et al. 1995; Heijmans et al.
2000; Mackness et al. 1997).
Cytokines are multifunctional polypeptides which are
synthesized by different cells in the body; they have
important roles in the development of cellular and humoral
reactions, the stimulation of inflammatory reactions, the
regularization of hematopoietin, the control of the increase
and differentiation of cells and the initiation of wound-
healing processes (O¨ztu¨rk 2001).
Cytokines like TNF-a, IL-1 and IL-6 have important
effects on the initiation and maintenance of particular
chemotaxis and inflammatory reactions. These mediators
have meditative and regulatory roles in the progress of
diabetic nephropathy and in all complications of diabetes
(Navarro et al. 2005).
Experimental diabetes models have an important place
in analyzing diabetes complications and determining
treatment approaches; in this study, we determined the
activities of PON and lipoprotein as well as the cytokine
profile to research the effect of lycopene on diabetes.
Materials and Methods
Material and Experiment Groups
Animals were provided by University of Yu¨zu¨ncu¨ Yıl
Experimental Animal Unit. Twenty-eight Wistar–Albino
rats aged 7–8 weeks were used. Rats weighed 300–350 g at
the start of the study. Experimental animals were chosen
randomly and categorized into four groups. The first was a
control group (n = 7), the second was a diabetes group
(n = 7), the third was a lycopene group (n = 7) and the
fourth was a diabetes-lycopene group (n = 7). Rats were
sheltered in cages, where they always had food and fresh
water in the 4-week experimental period.
The groups were as follows:
(1) Control group (C) In seven male rats weighing
300–350 g, with blood sugar levels calculated before
the experiment, a 45-mg/kg single dose of physio-
logical serum was injected intraperitoneally (i.p.)
Karabay et al. (2006).
(2) Group with diabetes but lycopene was not given (D)
In seven male rats weighing 300–350 g, with blood
sugar levels calculated before the experiment, a
45-mg/kg single dose of streptozotocin (STZ) (Sigma,
St. Louis, MO) was given in a cold citrate tampon
(pH 4.5) i.p. Karabay et al. (2006). After 72 h,
glucose levels in the blood samples taken from the tail
vein were determined through the Lever Chek-TD-
4222 biosensor glucose measuring device and strips.
Rats with a blood level [250 mg/dl were diagnosed
as having diabetes.
(3) Group with diabetes and given lycopene (D–L) In
seven male rats weighing 300–350 g, with blood
sugar levels calculated before the experiment, a
45-mg/kg single dose of STZ was given in a cold
citrate tampon (pH 4.5) i.p. After 72 h, glucose levels
in the blood samples taken from the tail vein were
determined with the Lever Chek-TD-4222 biosensor
glucose measuring device and strips. Rats with a
blood level [250 mg/dl were diagnosed as having
diabetes and given lycopene dissolved in corn oil,
10 mg/kg/day for 28 days by gavage orally.
(4) Group to which lycopene was given (L) In seven male
rats weighing 300–350 g, with blood sugar levels
calculated before the experiment, lycopene dissolved
in corn oil was given, 10 mg/kg/day for 28 days by
gavage orally.
Biochemical Analysis
For future use in the determination of HbA1c, lipoprotein
and PON activity and in the analysis of cytokine, lipo-
protein serum was put into Eppendorf tubes and frozen at
-18 C until the date of the experiment.
PON enzyme activity was determined using a com-
mercial kit of Rel Assay Diagnostics (Gaziantep, Turkey)
by a spectrophotometric method. While the levels of blood
HbA1c and blood serum lipoprotein (triglyceride, choles-
terol, VLDL, HDL, LDL) were analyzed using a com-
mercial kit (Roche Diagnostics, Mannheim, Germany) with
the Hitachi-911 autoanalyzer (Hitachi, Tokyo, Japan),
cytokine levels (TNF-a, IL-2, IL-6, IL-10) were analyzed
using the platen ELISA commercial kit of e-Bioscience
(San Diego, CA).
Statistical Analysis
All data were analyzed using ANOVA and the SAS pro-
gram (SAS Institute, Cary, NC).
Results
The levels of data belonging to the four groups are pre-
sented in Table 1.
In PON activity, a significant decrease in the diabetes
group compared to the control group, a slight increase in
622 S. C¸. Yegin et al.: Lycopene in Rats with Experimental Diabetes
123
the diabetes-lycopene group and a significant increase in
the lycopene group were found.
HbA1c levels were the highest in the diabetes group, the
value was closer to that of the control group in the diabetes-
lycopene group, and this value increased significantly in
the lycopene group compared to the control and diabetes-
lycopene group.
For triglyceride levels, a statistically significant increase
was recorded in the diabetes, diabetes-lycopene and lyco-
pene groups compared to the control group.
Cholesterol levels significantly decreased in the lyco-
pene and the diabetes groups compared to the control
group. A statistical result close to that of the control group
was recorded in the diabetes-lycopene group.
For VLDL, a significant increase was found in the dia-
betes, diabetes-lycopene and lycopene groups compared to
the control group.
For HDL, a significant decrease was observed in the
diabetes, diabetes-lycopene and lycopene groups compared
to the control group.
For LDL, a significant decrease in the lycopene, dia-
betes-lycopene and diabetes groups compared to the con-
trol group was observed.
When TNF-a, IL-2, IL-6 and IL-10 levels were ana-
lyzed, no significant difference was observed in the other
groups compared to the control group.
Discussion
DM is a metabolic and endocrine disease emerging due to
absolute or dependent insulin deficiency or due to insulin
resistance and characterized by a carbohydrate lipid and
protein metabolism disorder. During the progress of the
disease, specific complications such as retinopathy,
nephropathy, neuropathy and atherosclerosis occur; and
thousands of people die of such complications.
One of the most important among numerous diseases in
which changes in antioxidant defense systems are detected
is DM. In short, it is a disease which is often encountered in
various populations and carries with it many fatal
complications.
Among the complications of the disease are hypergly-
cemia, hyperlipidemia, glucosuria, polyphagia, polydipsia
and ketoacidosis; firstly, cardiovascular disorders in the
progressive aspects of micro- and macroangiopathies,
autonomic neuropathy, retinopathy and nephropathies take
place. Many investigations have focused on the important
role of oxidant stress in the development of complications
(Bell and Hye 1983; Giugliano et al. 1996).
Free radical–originated tissue damage causes pancreatic
b-cell dysfunction and prevents the use of glucose in sur-
rounding tissues by decreasing insulin secretion (Evans
et al. 2003; Ceriello and Motz 2004). Lycopene, with its
antioxidant feature, decreases the damage caused by oxi-
dative stress and lipid, protein and cellular components like
DNA by catching free radicals (Agarwal and Rao 2000).
In type 2 diabetes patients, using tomato juice,
depending upon the level of plasma lycopene, it has been
observed that harmful metabolic products in blood vessels
decrease with the oxidation of LDL cholesterol.
Serum carotenoids, among which lycopene exists, are
closely related to type 2 diabetes. The levels of glucose
metabolism and serum carotenoids depending upon
abnormalities of glucose tolerance show a linear decrease
(Coyne et al. 2005).
The production of free oxygen radical and lipid peroxide
increases, and the defense system is insufficient in diabetes.
Table 1 Results of PON, HbA1c, triglyceride, cholesterol, VLDL, HDL, LDL and cytokine in the DM, DM-lycopene, lycopene and control
groups
Group C D DL L p
(n = 7) (n = 7) (n = 7) (n = 7)
PON (U/L) 13.06 ± 1.35bc 4.61 ± 0.74c 16.58 ± 2.12b 34.11 ± 3.83a \0.001
HbA1c (%) 1.50 ± 0.04
b 6.74 ± 0.27a 2.38 ± 0.17b 3.71 ± 0.10c \0.001
Triglyceride (mg/dl) 60.32 ± 2.85b 185.71 ± 32.23a 158.77 ± 26.58a 188.40 ± 15.20a B0.001
Cholesterol (mg/dl) 66.00 ± 2.22a 53.71 ± 6.77ab 61.86 ± 3.35a 44.57 ± 2.40b \0.05
VLDL (mg/dl) 12.00 ± 0.58a 28.57 ± 4.75b 31.71 ± 5.34b 28.57 ± 2.63b \0.05
HDL (mg/dl) 31.57 ± 4.80b 15.29 ± 2.91a 15.00 ± 2.15a 8.43 ± 1.17a \0.001
LDL (mg/dl) 22.43 ± 4.52b 10.57 ± 1.53ab 15.14 ± 5.32ab 7.71 ± 0.81a \0.05
TNF-a (pg/ml) 45.66 ± 1.16 44.49 ± 1.01 51.17 ± 5.17 50.80 ± 4.44 [0.05
IL-2 (pg/ml) 400.21 ± 137.62 591.34 ± 106.02 309.17 ± 103.91 503.71 ± 115.04 [0.05
IL-6 (pg/ml) 33.03 ± 0.69 30.50 ± 1.65 38.17 ± 4.30 38.89 ± 4.20 [0.05
IL-10 (pg/ml) 189.04 ± 10.40 248.06 ± 53.69 253.74 ± 23.67 233.30 ± 41.56 [0.05
Values are means ± SEM. Letters signify statistically significant difference
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The increase of free radical production contributes to the
onset of diabetes complications and progression. Due to a
high glucose level, reactive oxidants causing oxidative
damage come out in diabetes. LDL oxidation is the key
factor in the development and progression of atheroscle-
rotic lesions. Changes in lipid composition and oxidative
stress cause lipid peroxidation in diabetes. On the other
hand, serum enzymes which have antioxidant features and
are carried with HDL prevent the oxidation of PON LDL
and HDL particles. Therefore, analysis of the relationship
between oxidation and PON enzyme helps us to reveal the
role of PON enzyme in diabetics (Aviram et al. 1999).
PON enzyme has the ability to protect HDL and LDL
from oxidation. Various mechanisms have been gaining
importance in the explanation of this protective role. It is
believed that the enzymes related to HDL (PON1, LCAT,
platelet activator factor acetylhydrolase platelet) prevent
lipoproteins from oxidative modifications (Mackness et al.
1998). PON protects LDL-K from oxidation which is
induced by Cu ion and free radicals (Heinecke 2000).
PON1 enzyme found in the HDL-K structure demolishes
active lipids in minimally modified LDL, so it may show a
protective effect against inflammatory response formation
in cells of the artery wall (Nelson and Cox 2000). PON
hydrolyzes cholesterol linoleate hydroperoxides in oxi-
dized LDL and specific oxidized phospholipids (Aviram
et al. 2000).
In the study, the levels of PON in the diabetes group
were significantly low in proportion to the diabetes-lyco-
pene, lycopene and control groups (p \ 0.001). The PON
enzyme level in the lycopene group was the highest in
proportion to the other groups. In previous studies
decreased PON1 activity in the diabetes group may have
occurred due to decreased specific activity or increased
oxidant substances because of glycation or an inhibitor in
circumvolution, as a result of decreasing of serum con-
centration (Valabhi et al. 2001; Gu¨rsu and O¨zdin 2002;
O¨ztu¨rk 2008). Our results support the protective effect of
lycopene with the data on PON1 activity.
Peripheral neuropathy caused by a decrease in the
capacity of lipid peroxide in diabetes supports the idea that
decreasing PON activity is related to increased irritability
against arteriosclerosis.
The level of PON-1 decreases in diabetics, in those with
KVH, in those who smoke, in hypercholesterolemia, in old
age, in obesity, in menopause and in renal insufficiency
(Aviram et al. 1999).
In the present study levels of triglyceride were high in
the diabetes and other groups in proportion to the control
group (p \ 0.001). The increase was two times higher in
proportion to the control group. As Deakin et al. (2005)
state in their studies, a positive relationship was deter-
mined in the serum PON-1, serum triglycerides, diabetes-
lycopene and lycopene groups in our study and a negative
relationship was observed between the group of PON-1-
activated diabetes and serum triglyceride. The levels of
total cholesterol were lower in the diabetes and lycopene
group in proportion to the control group (p \ 0.05). Again,
levels of VLDL were higher in the other groups compared
to the control group (p \ 0.05). The quantities of LDL
(p \ 0.05) and HDL (p \ 0.001) were lower in the other
groups compared to the control group. A remarkable result
is that the levels of LDL and HDL in the group to which
lycopene was given were much lower in proportion to the
other groups.
LDL cholesterol may be high or normal in diabetics.
Yet, small and dense arteriogenic LDL cholesterol
increases. LDL cholesterol [100 mg/dl increases cardio-
vascular mortality (Mahley et al. 2003).
That VLDL flow toward plasma is faster in type 2 dia-
betics increases LDL synthesis. VLDL affects LDL since it
is a precursor of LDL. Barakat et al. (1990) stated that the
cholesterol level in diabetics with normolipidemia and
hyperlipidemia and the level of triglyceride which LDL
and HDL contain increase and the level of cholesterol
decreases. These results are compatible with the results we
acquired in our study. Insulin has an effect on HMG-CoA
reductase and on the level of triglyceride/cholesterol in the
compound of LDL. Insulin deficiency or hyperinsulinemia
affects this proportion. In conclusion, LDL uptake
decreases and LDL accumulation occurs on the blood
vessel wall (Barakat et al. 1990).
Patients with 4086 type 2 DM were observed in the
United States in 2002, and the serum level of LDL in 58 %
of them was 130 mg/dl or more (Saaddine et al. 2002).
In their study on female mice with nonobese DM,
Schloot et al. (2002) asserted that the serum IFN-c level
was low with respect to the control group but that the
serum IL-10 level did not change.
Such cytolysis of TNF-a, IL-1 and IL-6 and primarily
chemotaxis have a substantial influence on starting the
inflammatory response and the continuation of it. These
function as mediators and stabilizers in the development of
diabetic nephropathy and all complications of diabetes
(Navarro et al. 2005). Dalla et al. (2005) found that serum
levels of acute-phase markers such as CRP, serum amyloid
A, fibrinogen and IL-6 are high.
In their study on female mice with diabetes after
6–8 weeks of STZ, Fidan et al. (2005) found an increase in
the level of serum IFN-c with regard to the control group
and that the levels of serum TNF-a, IL-1, IL-2, IL-6 and
IL-10 remained stable.
In research done on 85 patients with diabetes and 23
healthy subjects, although serum NO and IL-1b had a
synergic effect on the development of diabetes, no differ-
ence in the serum levels among the groups was observed;
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and as a result of this, no assessment can be carried out
about the functions of these parameters in diabetic patients
just by taking the levels of serum NO and IL-1b into
consideration (Yenisey et al. 2001).
Altinova et al. (2006) indicated that in patients with type
1 DM with and without diabetic microvascular complica-
tions there was no statistically significant difference among
the groups in terms of levels of serum TNF-a and IL-6.
In the study, the role of cytokines on diabetes and the
effects of lycopene on the levels of cytokine in the groups
with diabetes were examined. TNF-a increased in the lyco-
pene and lycopene-diabetes group with regard to the control
group, but this increase was not statistically significant.
Additionally, IL-2 was slightly high in the diabetic group
with regard to the other groups. Also, there was no difference
in the levels of IL-6 among the groups, but IL-10 increased a
bit in the other groups, especially in the diabetes-lycopene
and diabetes groups in comparison with the control group.
But this increase was not statistically important. Similar
results on many cytokines in diabetes have been obtained,
and it has been concluded that cytokine parameters cannot be
used in the evaluation of the pathogenesis of diabetes.
It is considered that the HDL level decreased in the
group with diabetes compared to the control group and that
the decrease observed in the diabetes-lycopene and diabe-
tes groups might be related to the decrease of cholesterol
level in these groups. Again, the level of LDL decreased in
the lycopene group in comparison with the other groups.
That the level of cholesterol with lycopene is low in
regard to the other groups indicates that lycopene has
characteristics that lower the level of cholesterol as well.
Because of the cholesterol-lowering feature of lycopene,
levels of LDL and HDL were low in the lycopene group.
Conclusion
The combination of diabetes and lycopene does not have an
impact on cytokines. On the other hand, the fact that there
is an increase in lycopene in the diabetes-lycopene group
and a significant decrease in the diabetes group considering
the results obtained from the level of PON enzyme, it can
be concluded that these are significant indications that
diabetes has oxidative and lycopene has preventive quali-
ties. Considering that oxidative stress has a role in forming
diabetes and its complications, such alternative methods as
lycopene and supportive treatment approaches should be
researched and developed.
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